Cardiometabolic risk management moved forward with practical signals for monitoring and understanding disease biology. A real-world study reported that Nefecon, a targeted-release budesonide formulation, reduced proteinuria and preserved kidney function in primary IgA nephropathy, including in patients with lower baseline protein leakage. In oncology supportive care, a diabetes monitoring pathway study focused on keeping older cancer patients safe during steroid therapy, reflecting a common but under-addressed cause of hyperglycemia-related complications in routine practice. On the obesity–gut–metabolism axis, a mechanistic intestinal story described an oxygen-sensing approach that shielded against obesity but did not add benefit when combined with weight-loss surgery, underscoring the limits of translating intestinal biology into additive clinical outcomes. The combined message: measurement and mitigation strategies are increasingly becoming part of standard-of-care execution, not just research endpoints.